INDIA PHARMA was conceptualized in 2016 by the Federation of Indian Chambers of Commerce & Industry in partnership with the Department of Pharmaceuticals as a strategic platform for industry–government dialogue. The initiative was designed to identify growth opportunities, address sectoral challenges, and create a roadmap for advancing India’s pharmaceutical ecosystem.

Over the past eight editions, INDIA PHARMA has evolved into a premier global forum bringing together policymakers, regulators, industry leaders, academia, and international stakeholders. The platform has played a pivotal role in shaping India’s pharmaceutical sector through policy discourse, issue resolution, and strategic collaborations.

INDIA PHARMA has evolved significantly over the years, with each edition reflecting the changing priorities and growth trajectory of India’s pharmaceutical sector. The 1st Edition (2016) focused on “Make in India – Are We on Track?”, setting the tone for domestic manufacturing and self-reliance. The 2nd Edition (2017) emphasized “Responsible Healthcare”, highlighting accessibility and accountability. The 3rd Edition (2018) focused on “Driving NextGen Pharmaceuticals”, underscoring innovation and future-ready capabilities, followed by the 4th Edition (2019) on “Enhancing Affordable Pharmaceutical Healthcare”.

The 5th Edition (2020) centered on “Meeting Challenges for Affordable and Quality Healthcare”, reflecting resilience and quality systems. The 6th Edition (2021), themed “India Pharma Industry: Future is Now”, signaled a shift towards transformation and global positioning. The 7th Edition (2022) advanced this vision through “Vision 2047: Transformative Roadmap for the Future”, aligning with long-term national goals. The 8th Edition (2023) focused on “Indian Pharma Industry: Delivering Value Through Innovation”, reinforcing innovation-led growth.

A defining feature of INDIA PHARMA has been the flagship CEOs’ Roundtable, enabling direct, high-level interactions between industry leaders and government. This forum has emerged as a key mechanism for candid discussions on policy priorities, regulatory challenges, and future growth pathways.

Building on this strong legacy, the theme of the 9th Edition (2026) is  “Discover in India: Leapfrogging Life-Sciences Innovation”, aiming to position India at the forefront of global pharmaceutical leadership and healthcare transformation.

                             

The event is jointly organized by the Department of Pharmaceuticals (DoP) and FICCI. The DoP plays a central role in policy formulation, ensuring access to affordable medicines, promoting research and development, and strengthening global competitiveness. FICCI serves as a key industry interface for policy advocacy, industry representation, and consensus building.

India’s pharmaceutical industry is a global leader, ranking 3rd by volume and 14th by value, and contributing approximately 1.7% to GDP. The sector is valued at around US$50 billion and is projected to reach US$130 billion by 2030, with exports exceeding US$30 billion. India has also demonstrated global leadership in public health through initiatives such as Vaccine Maitri, supplying nearly 300 million doses to around 100 countries.

India’s biotechnology sector is also rapidly expanding, ranked among the top 12 globally and 3rd in the Asia-Pacific region. With a valuation of approximately US$137 billion and a target of US$300 billion by 2030, the sector is driven by innovation, startup growth, and strong research infrastructure.

Against this backdrop, the 9th edition of INDIA PHARMA will be held on 13^th–14^th April 2026 in New Delhi, marking the continuation of a strong legacy and providing a future-oriented platform to shape the next phase of sectoral growth.

The 9th edition will focus on building a future-ready, globally competitive pharmaceutical ecosystem by promoting innovation, strengthening regulatory frameworks, and enhancing ease of doing business. It aims to position India as a global hub for pharmaceuticals and biotechnology by boosting investments, expanding exports, and fostering international collaborations. The event will feature a comprehensive set of engagements, including the flagship CEOs' Roundtable.

Key thematic sessions will cover policy thrust for catalysing innovation, enabling a regulatory ecosystem to foster innovation, harnessing next-generation technologies for disruptive innovation, addressing regulatory challenges, and reflections on big moves required to leapfrog innovation. Strategic focus areas include unlocking India's CRDMO potential, regulatory agility, digital transformation, biologics and advanced therapies, supply chain resilience, developing a vibrant pharma financing ecosystem, and a startup showcase platform for emerging innovations.

Expected outcomes include actionable policy recommendations, strengthened global partnerships and investment pipelines, enhanced regulatory clarity, and reinforcement of India's position as a reliable global supplier of affordable, high-quality medicines. INDIA PHARMA 2026 will play a critical role in shaping India's pharmaceutical sector roadmap and positioning the country at the forefront of global healthcare innovation and manufacturing excellence.

*****

CMC-DoP

(Release ID: 2250771) Visitor Counter : 447